- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00049335
S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
Protocol For Assessment Of Capecitabine For Advanced Colorectal Cancer In Patients Aged 70 Years And Older (And In A Cohort Of Patients Younger Than 60 Years)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating older patients who have metastatic or recurrent colorectal cancer that cannot be surgically removed.
Descripción general del estudio
Descripción detallada
OBJECTIVES:
- Determine the feasibility of enrolling patients aged 70 and over with unresectable metastatic or recurrent colorectal cancer to a structured phase II study.
- Determine the anticancer efficacy of capecitabine, in terms of objective response rate (confirmed and unconfirmed, complete and partial responses) and 2-year survival, in these patients.
- Determine the toxicity and tolerability of this drug in these patients.
- Determine the feasibility of using standardized self-report measures of comorbidity, depression, and functional status of patients treated with this drug.
- Determine the clinical pharmacology of this drug in these patients.
- Determine whether patients under 60 years of age treated with this drug have clinical pharmacologic parameters similar to those reported in the literature.
OUTLINE: This is a multicenter study. Patients are stratified according to age (70 and over vs 18 to 59).
Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 80 patients (60 patients aged 70 and over, 20 patients aged 18 to 59) will be accrued for this study.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Mobile, Alabama, Estados Unidos, 36607
- MBCCOP - Gulf Coast
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006-2726
- CCOP - Western Regional, Arizona
-
Phoenix, Arizona, Estados Unidos, 85012
- Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
-
Tucson, Arizona, Estados Unidos, 85723
- Veterans Affairs Medical Center - Tucson
-
Tucson, Arizona, Estados Unidos, 85724
- Arizona Cancer Center at University of Arizona Health Sciences Center
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
Little Rock, Arkansas, Estados Unidos, 72205
- Veterans Affairs Medical Center - Little Rock
-
-
California
-
Duarte, California, Estados Unidos, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Estados Unidos, 92357
- Veterans Affairs Medical Center - Loma Linda (Pettis)
-
Los Angeles, California, Estados Unidos, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, Estados Unidos, 90033
- USC/Norris Comprehensive Cancer Center and Hospital
-
Martinez, California, Estados Unidos, 94553
- Veterans Affairs Outpatient Clinic - Martinez
-
Oakland, California, Estados Unidos, 94609-3305
- CCOP - Bay Area Tumor Institute
-
Orange, California, Estados Unidos, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Cancer Center
-
Santa Rosa, California, Estados Unidos, 95403
- CCOP - Santa Rosa Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80010
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
Denver, Colorado, Estados Unidos, 80220
- Veterans Affairs Medical Center - Denver
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20060
- MBCCOP - Howard University Cancer Center
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Veterans Affairs Medical Center - Tampa (Haley)
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342-1701
- CCOP - Atlanta Regional
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Veterans Affairs Medical Center - Chicago (Westside Hospital)
-
Chicago, Illinois, Estados Unidos, 60612
- MBCCOP - University of Illinois at Chicago
-
Decatur, Illinois, Estados Unidos, 62526
- CCOP - Central Illinois
-
Hines, Illinois, Estados Unidos, 60141
- Veterans Affairs Medical Center - Hines
-
Maywood, Illinois, Estados Unidos, 60153-5500
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160-7353
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
Wichita, Kansas, Estados Unidos, 67214-3882
- CCOP - Wichita
-
Wichita, Kansas, Estados Unidos, 67218
- Veterans Affairs Medical Center - Wichita
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40502-2236
- Veterans Affairs Medical Center - Lexington
-
Lexington, Kentucky, Estados Unidos, 40536-0084
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Veterans Affairs Medical Center - New Orleans
-
New Orleans, Louisiana, Estados Unidos, 70112
- MBCCOP - LSU Health Sciences Center
-
New Orleans, Louisiana, Estados Unidos, 70112
- Tulane Cancer Center at Tulane University Hospital and Clinic
-
Shreveport, Louisiana, Estados Unidos, 71130-3932
- Louisiana State University Health Sciences Center - Shreveport
-
Shreveport, Louisiana, Estados Unidos, 71101-4295
- Veterans Affairs Medical Center - Shreveport
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Cancer Research Center at Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- CCOP - Michigan Cancer Research Consortium
-
Ann Arbor, Michigan, Estados Unidos, 48109-0948
- University of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, Estados Unidos, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, Estados Unidos, 48201-1932
- Veterans Affairs Medical Center - Detroit
-
Detroit, Michigan, Estados Unidos, 48202
- Josephine Ford Cancer Center at Henry Ford Health System
-
Grand Rapids, Michigan, Estados Unidos, 49503
- CCOP - Grand Rapids
-
Royal Oak, Michigan, Estados Unidos, 48073-6769
- CCOP - Beaumont
-
Southfield, Michigan, Estados Unidos, 48075
- Providence Cancer Institute at Providence Hospital - Southfield
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216-4505
- University of Mississippi Medical Center
-
Jackson, Mississippi, Estados Unidos, 39216
- Veterans Affairs Medical Center - Jackson
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, Estados Unidos, 63141
- CCOP - St. Louis-Cape Girardeau
-
Saint Louis, Missouri, Estados Unidos, 63110
- St. Louis University Hospital Cancer Center
-
Springfield, Missouri, Estados Unidos, 65807
- CCOP - Cancer Research for the Ozarks
-
-
Montana
-
Billings, Montana, Estados Unidos, 59101
- CCOP - Montana Cancer Consortium
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87108-5138
- Veterans Affairs Medical Center - Albuquerque
-
Albuquerque, New Mexico, Estados Unidos, 87131
- MBCCOP - University of New Mexico HSC
-
-
New York
-
New York, New York, Estados Unidos, 10016
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
-
New York, New York, Estados Unidos, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University
-
Rochester, New York, Estados Unidos, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
North Carolina
-
Goldsboro, North Carolina, Estados Unidos, 27534-9479
- CCOP - Southeast Cancer Control Consortium
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45220-2288
- Veterans Affairs Medical Center - Cincinnati
-
Cincinnati, Ohio, Estados Unidos, 45267-0501
- Charles M. Barrett Cancer Center at University Hospital
-
Cleveland, Ohio, Estados Unidos, 44195-9001
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, Estados Unidos, 43206
- CCOP - Columbus
-
Dayton, Ohio, Estados Unidos, 45429
- CCOP - Dayton
-
Dayton, Ohio, Estados Unidos, 45428-1002
- Veterans Affairs Medical Center - Dayton
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Oklahoma University Medical center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97207
- Veterans Affairs Medical Center - Portland
-
Portland, Oregon, Estados Unidos, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, Estados Unidos, 97201-3098
- Cancer Institute at Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Charleston, South Carolina, Estados Unidos, 29401-5799
- Veterans Affairs Medical Center - Charleston
-
Greenville, South Carolina, Estados Unidos, 29615
- CCOP - Greenville
-
Spartanburg, South Carolina, Estados Unidos, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38104
- Veterans Affairs Medical Center - Memphis
-
Memphis, Tennessee, Estados Unidos, 38104
- University of Tennessee Cancer Institute at Methodist Central Hospital
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79106
- Harrington Cancer Center
-
Amarillo, Texas, Estados Unidos, 79106
- Veterans Affairs Medical Center - Amarillo
-
Fort Sam Houston, Texas, Estados Unidos, 78234-6200
- Brooke Army Medical Center
-
Galveston, Texas, Estados Unidos, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, Estados Unidos, 77030-4095
- University of Texas - MD Anderson Cancer Center
-
San Antonio, Texas, Estados Unidos, 78229-3900
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Estados Unidos, 78229
- Veterans Affairs Medical Center - San Antonio (Murphy)
-
Temple, Texas, Estados Unidos, 76504
- Veterans Affairs Medical Center - Temple
-
Temple, Texas, Estados Unidos, 76508
- CCOP - Scott and White Hospital
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84148
- Veterans Affairs Medical Center - Salt Lake City
-
Salt Lake City, Utah, Estados Unidos, 84112-5550
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- CCOP - Virginia Mason Research Center
-
Seattle, Washington, Estados Unidos, 98108
- Veterans Affairs Medical Center - Seattle
-
Seattle, Washington, Estados Unidos, 98109
- Puget Sound Oncology Consortium
-
Tacoma, Washington, Estados Unidos, 98405-0986
- CCOP - Northwest
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed metastatic or recurrent colorectal cancer not amenable to surgical resection
- Measurable disease
- No known brain metastases by MRI or CT scan
PATIENT CHARACTERISTICS:
Age
- 70 and over OR
- 18 to 59
Performance status
- Zubrod 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute granulocyte count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- SGOT (serum glutamate oxaloacetate transaminase) or SGPT (serum glutamate pyruvate transaminase) no greater than 2 times ULN
Renal
- Creatinine no greater than 2 times ULN
- Creatinine clearance greater than 50 mL/min
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- HIV negative
- No known seizure disorder
- No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer currently in complete remission, or any other cancer for which the patient has been disease free for 5 years
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy for advanced cancer
- Prior adjuvant chemotherapy allowed provided recurrence occurred more than 1 year after the last treatment
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- At least 4 weeks since prior sorivudine or brivudine
- No concurrent sorivudine or brivudine
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Capecitabine
Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
|
1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, on Days 1-14 of 21 day cycle
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Feasibility of enrolling patients aged 70 years or older to a Phase II trial including pharmacokinetic sampling
Periodo de tiempo: Registration
|
Registration
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Toxicidad
Periodo de tiempo: 3 años
|
3 años
|
|
Efficacy of capecitabine for management of advanced colorectal cancer patients aged 70 years or older based on objective response rate and 2 year survival
Periodo de tiempo: 2 years
|
2 years
|
|
Assess parameters of clinical pharmacology of capecitabine in patients aged 70 years or older including half life value(s), AUC (area under curve) and steady state levels
Periodo de tiempo: 3 years
|
3 years
|
|
Assess whether patients under 60 years have clinical pharmacologic parameters similar to those reported in the literature
Periodo de tiempo: 3 years
|
3 years
|
|
Explore, at a preliminary level, the feasibility of studying genetic polymorphisms and gene expression levels of enzymes involved in drug metabolism and resistance to capecitabine
Periodo de tiempo: 3 years
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Mecanismos moleculares de acción farmacológica
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Capecitabina
Otros números de identificación del estudio
- CDR0000258049
- U10CA032102 (Subvención/contrato del NIH de EE. UU.)
- S0030 (Otro identificador: SWOG)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer colonrectal
-
Istanbul Aydın UniversityTerminado
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos